Opana ER

Opana ER Was Withdrawn from the U.S. Market

Opana ER was the brand name for an extended-release oxymorphone opioid product intended for around-the-clock management of severe pain in selected opioid-tolerant patients. It should not be offered for sale. In June 2017, FDA requested removal of reformulated Opana ER from the market after concluding that the product’s benefits no longer outweighed its risks. The manufacturer subsequently removed it from the U.S. market.

The decision followed postmarketing evidence of a significant shift toward injection abuse of the reformulated product, associated with serious public-health consequences, including an outbreak of HIV and cases of thrombotic microangiopathy. FDA’s action was notable because it was the first request to remove a marketed opioid pain medicine due to public-health consequences of abuse.

All BeonMed Opana ER purchasing options—including 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg and 40 mg listings—should be disabled. The page can remain only as an informational withdrawal and safety resource, or it can be redirected to a general clinician-led pain-management page.

What “Withdrawn” Means for Patients

Market withdrawal means an old Opana ER prescription or an online product listing should not be treated as a route to continue therapy. A patient who once received Opana ER needs a current pain assessment and a clinician-directed transition plan. It is not safe to search for leftover stock, overseas tablets or a “generic Opana ER equivalent” based only on milligram strength.

Oxymorphone may exist in other regulatory or clinical contexts, but that does not make a product labeled Opana ER currently approved or suitable. Brand history, immediate-release and extended-release dosage forms, and products from different markets must not be conflated.

Do Not Abruptly Replace or Stop Long-Term Opioid Therapy

A patient who is still taking any oxymorphone product should contact the prescriber and dispensing pharmacist promptly. Do not abruptly stop a regularly used opioid, replace it with another opioid or calculate an “equivalent dose” from an online chart. Opioid conversions are clinically complex and incomplete cross-tolerance can lead to overdose.

Physical dependence may cause withdrawal when an opioid is stopped suddenly. Symptoms can include restlessness, sweating, runny nose, yawning, abdominal cramps, diarrhea, vomiting, anxiety, insomnia and increased pain. A clinician can design a gradual transition or taper and address the underlying pain.

Withdrawal alone is not usually treated by buying an unverified opioid. Patients with loss of control, craving, continued use despite harm or hazardous use should be evaluated for opioid use disorder and offered evidence-based care.

Why Extended-Release Opioids Carry High Consequence

Extended-release opioids contain a larger amount of active medicine designed to release over time. Crushing, chewing, dissolving or injecting such a product can release a potentially fatal amount rapidly. Abuse-deterrent design does not make an opioid abuse-proof or safer to manipulate.

Opioids can suppress the brain’s drive to breathe. Risk rises when treatment starts, the dose changes, another depressant is added or the patient has chronic lung disease, sleep apnea, frailty or older age.

• Slow, shallow, irregular or stopped breathing.
• Inability to wake or extreme limpness.
• Blue or gray lips and fingertips.
• Pinpoint pupils, choking or gurgling.
• Collapse or severe confusion.

Call emergency services immediately for suspected overdose and administer naloxone if available. The person still needs emergency observation because naloxone may wear off before a long-acting opioid.

Opioids, Benzodiazepines and Alcohol Can Be Fatal Together

Combining an opioid with alprazolam, lorazepam, clonazepam, diazepam or another benzodiazepine can cause profound sedation, respiratory depression, coma and death. Z-drug sleep medicines, alcohol, muscle relaxants, gabapentin, pregabalin, sedating antihistamines and other opioids can further increase risk.

A patient transitioning from Opana ER or another opioid should give every clinician and pharmacist a complete medication list. A new dental or surgical prescription can create dangerous duplication.

Why Old or Online Opana ER Listings Are High-Risk

Because the branded product was withdrawn, a website claiming fresh U.S. Opana ER stock raises serious questions. The item may be old, diverted, counterfeit, mislabeled or sourced outside a regulated supply chain. A matching imprint or bottle image does not prove authenticity.

Counterfeit opioid tablets may contain fentanyl or another potent substance. A person cannot reliably identify fentanyl by color, taste or appearance. The only safe response to a suspicious Opana ER listing is not to order or use it.

• No Opana ER sale or add-to-cart button should remain active.
• Do not advertise “cheap,” “overnight” or “without prescription.”
• Do not imply that discontinued stock is an equivalent substitute.
• Do not provide manipulation or conversion instructions.
• Direct existing patients to their prescriber and pharmacist.

What a Former Opana ER Patient Should Discuss with a Clinician

The review should identify the current pain diagnosis, functional goals, previous therapies, opioid tolerance, withdrawal risk, other sedatives, breathing disorders and substance-use history. The clinician may consider non-opioid medicines, physical rehabilitation, behavioral pain approaches, procedures or another carefully selected opioid when benefits outweigh risks.

No alternative is a direct one-to-one replacement based on tablet strength. The prescriber needs to account for incomplete cross-tolerance, formulation differences and individual health. The plan should include follow-up after any transition.

Naloxone and Household Overdose Planning

Anyone exposed to an opioid—and the people around them—should know the signs of overdose and how to use naloxone. Risk can remain after a medicine is changed if old tablets are still in the home or another opioid is prescribed.

Store naloxone where a responder can access it quickly. Call emergency services after giving it. Repeat administration may be needed according to the product instructions, especially with long-acting or highly potent opioids.

Secure Storage and Disposal of Remaining Tablets

Do not use or share an old Opana ER supply. Keep any remaining controlled medicine locked in its original labeled container until it can be disposed of. An authorized take-back location is preferred.

If take-back is not promptly available, ask a pharmacist or follow current FDA disposal instructions for the exact product. The risk of accidental or intentional ingestion must be weighed when choosing a disposal method. Never discard tablets loosely where another person or animal can find them.

Signs That Opioid Use Disorder Needs Assessment

Opioid use disorder is a treatable medical condition. Possible signs include taking more than intended, repeated unsuccessful attempts to cut down, craving, obtaining opioids from multiple sources, continued use despite harm, hazardous use or major time spent finding and recovering from opioids.

Seeking help should not result in abrupt abandonment. Evidence-based treatment may include buprenorphine, methadone or naltrexone along with behavioral and recovery support, depending on the patient. Emergency care is appropriate for overdose or immediate danger.

How This Page Can Serve Users Without Selling Opana ER

The page should clearly state the U.S. withdrawal, explain why active sales are inappropriate, describe overdose response and provide a pathway to current clinical care. This serves the search intent of people looking up an old medicine while avoiding false availability claims.

Search optimization should focus on accurate terms such as “Opana ER withdrawn,” “why was Opana ER removed,” “oxymorphone ER safety” and “what should former Opana ER patients do.” It should not target transactional phrases that imply the product can still be lawfully supplied.

Why Thrombotic Microangiopathy Was Part of the Concern

Thrombotic microangiopathy is a serious disorder involving injury to small blood vessels, low platelets and damage to organs such as the kidneys. Cases were reported in connection with intravenous abuse of reformulated Opana ER. This was not an ordinary side effect of taking a tablet as prescribed; it was part of the severe public-health harm linked to manipulation and injection.

Symptoms such as unusual bruising, severe weakness, confusion, reduced urination or other signs of acute illness require emergency evaluation. A historical exposure does not allow diagnosis from symptoms alone.

The HIV Outbreak Shows That Product Harm Can Extend Beyond One User

Injection of manipulated tablets and sharing injection equipment contributed to an HIV outbreak in rural Indiana. This demonstrates why FDA considered community consequences as well as individual pain relief. Hepatitis and bacterial infections can also spread through unsafe injection.

People who have injected opioids should be offered nonjudgmental HIV and hepatitis testing, sterile-equipment services where available, vaccination, overdose prevention and treatment for opioid use disorder.

Modern Pain Care Uses a Functional, Layered Plan

Chronic pain may respond best to several coordinated approaches rather than a single stronger opioid. Depending on the diagnosis, a plan may include physical or occupational therapy, graded activity, sleep treatment, behavioral pain therapy, non-opioid medicine, an interventional procedure or specialist review.

Improvement can be measured by walking, working, sleeping, caring for family or participating in rehabilitation. A lower pain score without better function may not justify serious opioid risk.

Remove Legacy Sales Content and Child Product Pages

Updating only the parent description is not enough if strength-specific Opana ER pages remain indexed with prices and add-to-cart buttons. Remove or redirect those child pages, product variations, structured product offers, stock status and merchant-feed entries.

Use a clear editorial note with the date of review and link to FDA’s withdrawal information. If old pages receive useful backlinks, redirect them to the informational Opana ER withdrawal page rather than to another opioid sales page.

Search snippets can remain stale after a page is changed. Request re-crawling after removing purchase claims and monitor indexed titles and merchant listings.

Frequently Asked Questions About Opana ER

What was Opana ER?

Opana ER was an extended-release oxymorphone opioid product used for selected severe, around-the-clock pain.

Is Opana ER still available in the United States?

No. The manufacturer removed reformulated Opana ER from the U.S. market in 2017 after FDA requested its removal.

Why did FDA request its removal?

FDA concluded that its benefits no longer outweighed the public-health risks associated with abuse, particularly injection abuse and related serious harms.

Should an online store sell Opana ER?

No active purchase listing should represent withdrawn Opana ER as a currently available U.S. medicine.

What should BeonMed do with Opana ER variations?

Disable all strengths, quantities, prices and add-to-cart functions and use the page only for withdrawal and safety information.

Can a patient switch to another opioid with the same milligram dose?

No. Opioid conversions are not one-to-one and require clinician management because overdose can result.

Should a long-term user stop suddenly?

Not without medical guidance. Abrupt stopping can cause withdrawal and destabilize pain and health.

What are opioid-overdose signs?

Slow or stopped breathing, inability to wake, blue lips, pinpoint pupils and collapse require emergency care.

What does naloxone do?

Naloxone can temporarily reverse opioid overdose. Give it as directed and call emergency services immediately.

Can Opana ER be crushed?

No. Manipulating an extended-release opioid can release a potentially fatal amount and was never a safe use.

Is an old prescription proof that a new online supply is legitimate?

No. A prior prescription does not authenticate current products or authorize purchase of a withdrawn brand.

Can pill appearance prove authenticity?

No. Counterfeit tablets can copy color, shape and imprint and may contain fentanyl or another unexpected substance.

What should be done with leftover Opana ER?

Secure it from others and use an authorized take-back option or follow current pharmacist and FDA disposal instructions.

What are safer next steps for pain?

Obtain a current pain assessment and discuss non-opioid, rehabilitative, interventional and carefully monitored prescription options.

What if a person cannot control opioid use?

Seek evaluation for opioid use disorder. Effective medication and behavioral treatments are available.

Can alcohol or Xanax be used with an opioid?

The combination can cause fatal respiratory depression and should not be used outside a tightly managed clinical plan.

Why keep this URL live at all?

It can answer historical and safety questions, but it must not function as a sales page or imply current availability.

What search terms are appropriate for the page?

Use informational terms about withdrawal, safety, overdose response and current pain care—not purchase-intent claims.

Medical and Regulatory References

• FDA: Request for removal of Opana ER
• FDA: Safety concerns from misuse of abuse-deterrent opioids
• FDA: Opioid medications
• FDA: Where and how to dispose of unused medicines

Medical disclaimer: This page documents a withdrawn product and does not recommend or offer Opana ER. A person using oxymorphone or another opioid should contact a licensed prescriber before making changes. Call emergency services for suspected overdose.